Integrated Biosciences announces a drug discovery platform that enables precise control of the integrated stress response, a biological pathway activated by cells in response to various pathological conditions. The new platform uses optogenetic technique to study the ISR in live cells without physical or chemical damage.
Researchers from Integrated Biosciences developed an AI platform to discover novel senolytic compounds, a class of molecules targeting age-related processes. The platform identified three highly selective and potent compounds with favorable medicinal chemistry properties.
Data from Neuroscience 2018 presents genetic deletion of SARM1 protecting axons and reducing biomarkers of neurodegeneration. SARM1 inhibition provides critical insight into developing disease-modifying therapeutics for patients with axonal degeneration.
The Phase 1/2 clinical trial showed that SPK-9001 reduced annualized bleeding rate by 97% and factor IX concentrate use by 99% in participants with hemophilia B. The data suggest a one-time infusion of SPK-9001 may sustain factor IX activity levels, reducing bleeding episodes.
The Phase 3 clinical trial data showed statistically significant and clinically meaningful improvements in functional vision and visual field in participants with RPE65-mediated inherited retinal disease. Participants demonstrated marked gains in full-field light sensitivity and peripheral vision.